An update on the management of immune thrombocytopenic purpura and emerging treatment options: A review and case report

Authors

  • Rithu Krishnan HSK College of pharmacy, Bagalkot, Karnataka
  • Mohammed Faisal K P Clinical Pharmacist, General Medicine, ASTER Malabar Institute of Medical Sciences, Govindapuram, Calicut, Kerala-673016, India.
  • Merlin T S Doctor of pharmacy (Pharm D), Krupanidhi College Of Pharmacy, Carmelaram P.O, Bangalore-560035
  • Cijo Oommen 4Clinical Pharmacist, Pediatrics and Neonatology, ASTER Malabar Institute of Medical Sciences, Govindapuram, Calicut, Kerala-673016

DOI:

https://doi.org/10.7439/ijpr.v6i7.3416

Abstract

Immune thrombocytopenic purpura affects both children and adults. It is an autoimmune disorder characterised by persistent thrombocytopenia (peripheral platelet count of less than 150 x109/L) due to autoantibody binding to platelet antigen(s) causing their premature destruction by the reticulo-endothelial system, in particular the spleen. There is no gold standard diagnostic test to confirm ITP. The diagnosis of ITP remains clinical and is based principally on the exclusion of other causes of thrombocytopenia by the history, physical examination, full blood count, peripheral blood film and autoimmune screen. Medical options for front-line drug therapy are corticosteroids, intravenous immunoglobulin, and intravenous Rh anti-D. Second and third line therapy includes monoclonal antibodies and thrombopoirtin receptor agonist. Transfusion of platelet is warranted if life threatening hemorrhage occurs. This review gives a brief discussion on the pathophysiology, clinical presentation, diagnosis and treatment of Immune Thrombocutopenic Purpura and a case report.

Downloads

Download data is not yet available.

References

Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol. 2003 Aug. 25(8); 660-4.

Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost.2008. 99: 4-13.

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009. 113: 2386-2393.

Choi SI, McClure PD. Idiopathic thrombocytopenic purpura in childhood. Can Med Assoc J. 1967. 97: 562-568.

Heitinik-Polle KM, Nijsten J, Boonacker CW, de Haas, Burin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a meta-analysis. Blood. 2014; 124(22):3295-307.

Kutter DJ, Bussel JB, Lyons RM. Efficiency of romiplostim in patients with chronic immune thrombocytopenic purpura: a double blinded randomized controlled trial. Lancet. 2008 Feb. 371(6910); 395-403.

Nugent D, McMillan R, Nichol JL, Slicher SJ. Pathogenesis of chronic ITP: increased platelet destruction and/or decresed platelet production. Br J Haematol. 2009. 146(6):585.

DiMaggio D, Andreson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol. 2009. 146(1):104.

Wright JF, Blanchette VS, Wang H, Arya N, Petric M, Semple JW, et al. Charecteristics of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura. Br J Haematol. 1996. 95(1):145.

Zhang W, Nardi MA, Borkowsky W, Li Z, Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C related immunologic thrombocytopenia. Blood. 2009. 113(17):4086.

Cines DB, Liebman H, Stasi R. pathobiology of secondary immune thrombocytopena. Semin Hematol.2009. 46(1 suppl 2):S2.

Yu J, Heck S, Patel V, Levan J,Yu Y, Bussel JB, Yazdanbakhsh K. defective circulating CD25 regulatory T cell in patients with chronic immune thrombocytopenic purpura. Blood. 2008. 112(4):1325.

Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am. 2008 Apr; 55(2):393-420.

Clinical Practice Guideline on the Evaluation andManagement of Immune Thrombocytopenia (ITP). The American Society of Hematology (ASH) 2011.

Lacey JV, Penner JA. Management of ITP in adults. Semin Thromb Hemost. 1977. 3(3):160.

Linda Honey. Treatment pathway for patients with ITP. National health society, London. 2015.

George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88:3-40.

Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989; 320:974-980.

Sandler SG, Tutuncuoglu SO. Immune thrombocytopenic purpura

Carroll RR, Noyes WD, Kitchens CS. High-dose intravenous immunoglobulin therapy in patients with immune thrombocytopenic purpura. JAMA. 1983; 249:1748-1750.

Ibrahium N Nakhoul, Peter Kozuch, Mala Varma. Management of adult Immune Thrombocytopenic Purpura. Clinical Advances in Heamatology and Oncology. 2006 feb.4 (2):136-137.

Roberto Stasi, and Drew Provan. Management of Immune Thrombocytopenic Purpura in Adults. Mayo Clin Proc. 2004.79:504-522.

Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun.2005; 8:140.

Nazi I, Kelton JG, LarcheM, Snider DP, Heddle NM, Crowther MA, Cook RJ, Tinmouth AT, Mangel J, Arnold DM. Effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013 sep. 122(11):1946-53.

Arnold DM, Dentali F, Crowther MA, Cook RJ, Meyer RM, Lim W, Kelton JG, Fraser GA. Systemic review: efficiency and safety of rituximab for adults with ITP. Annals of Internal Medicine. 2007; 146:25-33.

Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remission of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013 Nov. 53(11): 2807-12.

Cheng G. thrombopoietin receptor agonists in the treatment of ITP. Rinsho Ketsueki. 2013 Oct. 54(10):1915-8.

Downloads

Published

2016-07-30

Issue

Vol. 6 No. 7 (2016): Jul

Section

Case Report

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Author must Submit Copyright form  After acceptance of Article

How to Cite

1.
Krishnan R, Faisal K P M, S MT, Oommen C. An update on the management of immune thrombocytopenic purpura and emerging treatment options: A review and case report. Int J of Pharmc Res [Internet]. 2016 Jul. 30 [cited 2025 Mar. 14];6(7):264-70. Available from: https://ssjournals.co.in/index.php/ijpr/article/view/3416
Crossref
Scopus
Google Scholar
Europe PMC